InvestorsHub Logo
Followers 1036
Posts 114648
Boards Moderated 13
Alias Born 06/10/2006

Re: ptk123 post# 37536

Thursday, 06/15/2017 8:12:30 AM

Thursday, June 15, 2017 8:12:30 AM

Post# of 55244
Considering this is what the company claims.


In October 2013 we had to cease trialing the process due to lack of
available and sustainable funds. The new initiative to generate investment into the company will allow us to
recommence these trials and move towards selling the product on the open market. As a result, the Company is still in
development and approval stage.
In February 2014 we appointed an IR company who are looking to raise the estimated $2million required to obtain
FDA approval of the patented process to make the product available to our targeted markets.

https://www.otcmarkets.com/financialReportViewer?symbol=TCEL&id=117970

Now jump forward to June 2015,which is the last update!


COMPANY STATEMENT
FROM: JOHN MEREDITH, CFO & DIRECTOR, Therapy Cells, Inc
We have been actively engaged in negotiations regarding the required funding for the Company as stated in the last quarterly Financial Statements posted on the OTC website. Whilst those negotiations have been successfully concluded and a long-term relationship entered into, there have been a number of problems regarding the mechanics and logistics of the agreement – some
have been local in nature and others as a result of global influences – all of which have been beyond our control.
We had hoped that the funding would be received by today and indicated as such in previous releases; the funding has now been delayed a further month and we have been given assurances that this deadline will be met.
The Board is, naturally, disappointed but we remain positive that the process for FDA approval can start in the very near future. As soon as we have any news we will issue a further statement.
Venice, Florida
June 30th, 2015


https://www.otcmarkets.com/ajax/showNewsReleaseDocumentById.pdf?id=15659